A Phase 1, Double-Masked, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability, and Pharmacokinetics of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 16 May 2018
Price : $35 *
At a glance
- Drugs Isunakinra (Primary)
- Indications Allergic conjunctivitis; Dry eyes
- Focus Adverse reactions; First in man
- Sponsors Eleven Biotherapeutics; Sesen Bio
- 16 May 2018 According to a Sesen Bio media release, Eleven Biotherapeutics changed its name to Sesen Bio.
- 27 Apr 2015 Results presented at the Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting, as per Eleven Biotherapeutics media release.
- 20 Feb 2014 New trial record